|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | PDL BioPharma, Inc. |
|---|---|
| Information provided by: | Facet Biotech |
| ClinicalTrials.gov Identifier: | NCT00028288 |
Purpose
The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.
| Condition | Intervention | Phase |
|---|---|---|
|
Asthma |
Drug: Daclizumab |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma |
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |
| Bensch Research Associates | |
| Stockton, California, United States, 95207 | |
| Southern California Research | |
| Mission Viejo, California, United States, 92691 | |
| Institute of Health Care Assessment, Inc. | |
| San Diego, California, United States, 92120 | |
| Medical Research Associates | |
| Long Beach, California, United States, 90806 | |
| United States, Colorado | |
| National Jewish Medical and Research Center | |
| Denver, Colorado, United States, 80206 | |
| Clinical Reserch Centers of Colorado | |
| Denver, Colorado, United States, 80230 | |
| United States, Florida | |
| Florida Center for Allergy and Asthma Reserch | |
| Miami, Florida, United States, 33176 | |
| United States, Georgia | |
| Rx Research | |
| Woodstock, Georgia, United States, 30188 | |
| United States, Illinois | |
| ICSL Clinical Studies | |
| Bloomington, Illinois, United States, 61704 | |
| Asthma and Allergy Center of Chicago, S.C. | |
| River Forest, Illinois, United States, 60305 | |
| United States, Massachusetts | |
| New England Clinical Studies | |
| North Dartmouth, Massachusetts, United States, 02747 | |
| United States, Minnesota | |
| Clinical Research Institute | |
| Minneapolis, Minnesota, United States, 55402 | |
| United States, New Jersey | |
| Princeton Center for Clinical Research | |
| Princeton, New Jersey, United States, 08540 | |
| United States, Oregon | |
| Allergy, Asthma, and Dermatology Research Center, LLC | |
| Lake Oswego, Oregon, United States, 97035 | |
| United States, Pennsylvania | |
| Valley Clinical Research Center | |
| Easton, Pennsylvania, United States, 18045 | |
| United States, Texas | |
| Pharmaceutical Research and Consulting, Inc. | |
| Dallas, Texas, United States, 75231 | |
| United States, Wisconsin | |
| University of Wisconsin Medical School | |
| Madison, Wisconsin, United States, 53792 | |
| Allergy and Respiratory Care Center | |
| Milwaukee, Wisconsin, United States, 53209 | |
More Information
| Study ID Numbers: | DAC-1003 |
| Study First Received: | December 19, 2001 |
| Last Updated: | August 2, 2008 |
| ClinicalTrials.gov Identifier: | NCT00028288 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Asthma Daclizumab anti-Tac monoclonal antibody anti-IL-2 Zenapax |
|
Bronchial Diseases Immune System Diseases Immunologic Factors Daclizumab Physiological Effects of Drugs Asthma Immunosuppressive Agents |
Pharmacologic Actions Lung Diseases, Obstructive Hypersensitivity Respiratory Tract Diseases Lung Diseases Hypersensitivity, Immediate Respiratory Hypersensitivity |
